Ekkehard Moessner

USPTO Granted Patents = 94 (Patent Applications = 102)

CIPO Patents = 12 (Patent Applications = 38)

EPO Patents = 60 (Patent Applications = 108)

Average Co-Inventor Count = 7.0

ph-index = 17

Forward Citations = 962(Granted Patents)

DiyaCoin

= 0.48

Inventors with similar research interests:

Location History:

Kruezlingen, CH (2019)
Kreuzlingen, CH (2011 - 2024)
Schlieren, CH (2020 - 2024)

Company Filing History:

47 out of 4,942

Hoffmann-la Roche Inc.

Bristol-myers Squibb Compnay

patents

8. 1 out of 277

Roche Sequencing Solutions, Inc.

patents

Years Active: 2011-2025

where 'Filed Patents' based on already Granted Patents

94 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12441812 - Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules (2025-10-14),

2. 12331134 - Trispecific antibodies specific for HER2 and a blood brain barrier receptor and methods of use (2025-06-17),

3. 12297263 - Humanized anti-Tau(PS422) antibodies and methods of use (2025-05-13),

4. 12291561 - Antigen binding receptors specific for mutated Fc domains (2025-05-06),

5. 12286486 - Anti-FAP antibodies and methods of use (2025-04-29),

6. 12258371 - Stabilized immunoglobulin domains (2025-03-25),

7. 12215155 - Antibodies binding to CD3 and CD19 (2025-02-04),

8. 12215152 - Humanized anti-human CD19 antibodies and methods of use (2025-02-04),

9. 12202870 - Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereof (2025-01-21),

10. 12139553 - T cell activating bispecific antigen binding molecules (2024-11-12),

11. 12129306 - Antibodies binding to STEAP-1 (2024-10-29),

12. 12103982 - T cell activating bispecific antigen binding molecules (2024-10-01),

13. 12098213 - Antibodies binding to HLA-A2/WT1 (2024-09-24),

14. 12038441 - CAR-T reporter based diagnostic assays to detect tumor antigens in cancer patients (2024-07-16),

15. 12000064 - Universal reporter cell assay for specificity test of novel antigen binding moieties (2024-06-04),

Title: The Innovative Mind of Ekkehard Moessner

Introduction: Ekkehard Moessner, located in Kreuzlingen, Switzerland, stands out as an accomplished inventor with a remarkable portfolio of 88 patents. His contributions to the field of biomedicine, particularly in antibody development, have made significant strides in advancing treatments for various diseases.

Latest Patents: Among his latest innovations are patents focusing on antibodies binding to CD3 and CD19. This invention relates to antibodies that not only activate T cells but also includes polynucleotides encoding such antibodies, along with vectors and host cells that utilize them. Furthermore, he has developed humanized anti-human CD19 antibodies. This antibody is characterized by specific amino acid sequences in its hypervariable regions and includes methods for its application in medical treatments.

Career Highlights: Throughout his illustrious career, Ekkehard Moessner has worked with prominent companies such as Hoffmann-La Roche Inc. and Roche Glycart AG. His expertise in the field has enabled him to lead projects that blend innovation with practical applications in health care, showcasing his dedication and skill as an inventor.

Collaborations: Ekkehard has collaborated with notable colleagues, including Christian Klein and Pablo Umana. Their collective efforts have contributed to advancing the understanding and capabilities of antibody therapies, significantly impacting the medical field.

Conclusion: Ekkehard Moessner’s impressive array of patents and collaborations marks him as a significant figure in the realm of pharmaceutical innovations. His work not only pushes the boundaries of science but also serves as a beacon of hope for patients requiring advanced therapeutic options.

This text is generated by artificial intelligence and may not be accurate.